Shots:
- CStone Pharmaceuticals has entered into an exclusive commercialization agreement with Arrotex for the commercialization of sugemalimab in Australia & New Zealand
- As per the deal, Arrotex will be responsible for regulatory submissions & obtain exclusive commercialization rights for sugemalimab in Australia & New Zealand across all approved & future indications
- In return, CStone will receive an upfront payment, regulatory & commercial milestones, and a profit share, while supplying sugemalimab to Arrotex
Ref: PRnewswire | Image: CStone & Arrotex | Press Release
Related News: Combotope Therapeutics and Boehringer Ingelheim Collaborate on Next-Generation Cancer Antibody Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
